Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD)

Thumann, Gabriele; Perdikomati-Dahmen, Maria; Izsvak, Zsuzsanna; Ivics, Zoltan; Garcia Layana, Alfredo; Ronchetti, Mattia; Petrovski, Goran; Scherman, Daniel; Aranda, Pablo; Pouillot, Séverine; Binder, Susanne; Johnen, Sandra; Van den Berg, Joost

doi:10.1089/humc.2015.2519

Scientific article

English

Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD)

ContributorsThumann, Gabriele

; Perdikomati-Dahmen, Maria; Izsvak, Zsuzsanna; Ivics, Zoltan; Garcia Layana, Alfredo; Ronchetti, Mattia; Petrovski, Goran; Scherman, Daniel; Aranda, Pablo; Pouillot, Séverine; Binder, Susanne; Johnen, Sandra; Van den Berg, Joost

Published inHuman Gene Therapy. Clinical Development, vol. 26, no. 2, p. 97-100

Publication date2015

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques

Research groups

Ophtalmologie expérimentale (925)

Citation (ISO format)

THUMANN, Gabriele et al. Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD). In: Human Gene Therapy. Clinical Development, 2015, vol. 26, n° 2, p. 97–100. doi: 10.1089/humc.2015.2519

Article (Published version)

CC0

Identifiers

PID : unige:111906
DOI : 10.1089/humc.2015.2519
PMID : 26086761

Journal ISSN2324-8645

551views

347downloads

Creation19/11/2018 16:23:00

First validation19/11/2018 16:23:00

Update15/03/2023 15:09:47

Status update15/03/2023 15:09:46

Last indexation31/10/2024 12:05:46

Archive ouverte UNIGE

Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD)

Technical informations